In this edition, FDA approves Tecvayli for multiple myeloma, radiation and hormone therapy slows progression of prostate cancer, and more.
Read the full coverage here:
FDA approves Tecvayli for advanced multiple myeloma
Adding radiation to hormone therapy slows progression of oligometastatic prostate cancer
Use of cannabis during cancer treatment may have ‘under-appreciated’ financial impact
Older cancer survivors at higher risk for bone fracture
Machine-learning approach using step counts predicts hospitalization during radiotherapy
References:
Chino F, et al. Abstract 24. Presented at: ASCO Quality Care Symposium; Sept. 30-Oct. 1, 2022; Chicago.
Friesner I, et al. Abstract 132. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; New Orleans.
Rees-Punia E, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5153.
Tang C, et al. Abstract LBA 05. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; San Antonio.
